LICENSING AND CONTRACT RESEARCH

ONCOBRITE^â

In Vivo GFP Imaging

FIELD:

• Fluorescent tumor models of all types
• Fluorescent cancer cell lines of all types
• Custom fluorescent cell line development
• Imaging systems fully installed
• Technical support from AntiCancer scientists
• GFP Infectious disease imaging
• GFP labeling of bacteria of interest
• Drug discovery, evaluation and development
• OncoBrite® patents:

US: 6,232,523; 6,759,038; 6,235,968; 6,251,384; 6,649,159; 6,905,831

Australia: 749,338

Numerous world-wide pending patents

• Contact Li Tang, Business Development Manager, for OncoBrite^® licensing, equipment and customized contract research: all@anticancer.com

Olympus OV100 Whole Mouse Imaging System: designed for OncoBrite^® Technology

MetaMouse^â- ANGIOMOUSE^â

• Evaluate and develop new effective drugs for metastasis and angiogenesis
• Green/Red fluorescent protein (GFP, RFP) tumor expression for quantitative functional imaging
• In vivo drug discovery and evaluation for tumor growth, metastasis, angiogenesis
• Whole-body functional imaging of drug efficacy on tumor growth, metastasis angiogenesis, gene expression, tumor cell trafficking
• Real-time in vivo visualization of tumor growth, metastasis, angiogenesis, gene expression
• More than 100 GFP/RFP-expressing tumor models available for MetaMouse^®/AngioMouse^®
• Orthotopic metastatic MetaMouse^®/AngioMouse^® models
• All types of agents can be evaluated: small molecules, proteins, genes
• In vivo high-throughput drug screening and evaluation
• Customized contract research for all types of drug discovery and evaluation
• Metastatic tumor models of cancer cell types
• Full license opportunities available
• Microsurgical and other technical support from AntiCancer staff

• Contact Li Tang, Business Development Manager, for licensing and customized contract research.

• MetaMouse^® Patents:

US: 5,491,284; 5,569,812

Japan: 2,664,261

Europe: 0437488

HDRA^â

HISTOCULTURE DRUG RESPONSE ASSAY

• Determination of best treatment options for individual patients for all solid tumor types
• Determination of optimal treatment for patients for whom there is no standard therapy
• Screening of compound libraries for activity on patient human tumors
• Contact Li Tang, Business Development Manager, for cancer patient treatment and contract research : all@anticancer.com
• HDRA^â Patents:

US: 5,424,909; 5,726,009

Europe: 714,448

DERMATEK^â

• Topical liposome-based targeting of hair follicle
• Small and large molecules can be targeted to hair follicle
• Toxicity testing on histocultured full-thickness mouse or human skin.
• Hair-growth stimulator and inhibitor drug discovery evaluation and development on histocultured mouse or human skin.
• Contact Li Tang, Business Development Manager, for DermaTek^â licensing and contract research: all@anticancer.com
• DERMATEK^® Patents:

US: 5,641,508, 5,753,263, 5,849,579, 5,914,126, 5,965,157, 6,224,901, 6,261,763, 6,399,380

Canada: 2,159,626

Europe: 573,606, 692972

Japan: 2,950,519, 2,950,520

ENZYMATIC Homocysteine Assay

TECHNICAL BULLETIN FEATURES

• Single-enzyme in vitro diagnostic assay for total homocysteine (tHcy) in plasma
• Assay is based on genetically-engineered recombinant homocysteine cleaving enzyme
• Excellent correlation with HPLC
• High precision
• High throughput with a linear calibration curve
• No immunochemical reactions
• Simplest and least total homocysteine assay
• 510(k) cleared

PRINCIPLE OF THE TOTAL ENZYMATIC HOMOCYSTEINE ASSAY

In the Enzymatic Homocysteine Assay, protein-bound tHcy is first reduced to free Hcy. Genetically-engineered recombinant homocysteinase (rHCYase) then reacts with the free Hcy to form hydrogen sulfide (H₂S), ammonia, and a-ketobutyrate:

tHcy -------------> a-ketobutyrate + NH₄ + H₂S

rHCYase

H₂S then reacts with a proprietary fluorophore to give a fluorescence or absorption change. For fluorescence, the excitation wavelength is 665 nm and the emission is at 690 nm. Absorbance can be read between 660 and 680 nm. The test is linear from 1 mM to 50 mM. The Enzymatic Homocysteine Assay has been specifically optimized to minimize any cross reactivity with cysteine and methionine.

AVAILABILITY

The Enzymatic Homocysteine Assay has 510 (k) FDA clearance for the Hitachi 912. Kits are now available. Contact Li Tang, Business Development Manager, at all@anticancer.com

SPECIMEN COLLECTION AND PREPARATION

EDTA-plasma is recommended for homocysteine determination. Storage should be at 4°C for short periods. For longer storage, samples should be kept frozen at -20°C or kept in 3-deazaadenosine. Overnight fasting is recommended before blood is drawn. Standardized sampling procedures are crucial.

ENZYMATIC HOMOCYSTEINE ASSAY PATENTS

US: 6,140,102; 5,985,540; 5,998,191; 6,066,467; 6,468,762; 6,448,446

Japan: 3,337,693

Europe: 1,265,846

Worldwide patents pending